Literature DB >> 23671006

Perspectives on treatment of metastatic castration-resistant prostate cancer.

Axel S Merseburger1, Joaquim Bellmunt, Cheryl Jenkins, Chris Parker, John M Fitzpatrick.   

Abstract

The arrival of several new agents--cabazitaxel, abiraterone acetate, enzalutamide, and radium-223--is changing the treatment options and management of patients with metastatic castration-resistant prostate cancer (mCRPC). Many other novel agents are also being investigated. As new drugs become approved, new treatment strategies and markers to best select which patients will best respond to which drug are needed. This review article is a summary of a European Treatment Practices Meeting, which was convened to discuss these latest data on novel agents and current treatment strategies in the mCRPC setting.

Entities:  

Keywords:  Abiraterone acetate; Cabazitaxel; Docetaxel; Enzalutamide; Metastatic castration-resistant; Prostate cancer; Treatment

Mesh：

Substances：

Year:  2013        PMID： 23671006      PMCID： PMC3662847          DOI： 10.1634/theoncologist.2012-0478

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  101 in total

Review 1.  Metastasis to bone: causes, consequences and therapeutic opportunities.

Authors:  Gregory R Mundy
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

Review 2.  Expression and function of androgen receptor coactivators in prostate cancer.

Authors:  Zoran Culig; Barbara Comuzzi; Hannes Steiner; Georg Bartsch; Alfred Hobisch
Journal:  J Steroid Biochem Mol Biol       Date:  2004-12-19       Impact factor: 4.292

3.  Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.

Authors:  J Y Henry; L Lu; M Adams; B Meyer; J B Bartlett; A G Dalgleish; C Galustian
Journal:  Prostate       Date:  2011-10-03       Impact factor: 4.104

4.  Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy.

Authors:  Guru Sonpavde; Gregory R Pond; William R Berry; Ronald de Wit; Andrew J Armstrong; Mario A Eisenberger; Ian F Tannock
Journal:  Urol Oncol       Date:  2010-10-02       Impact factor: 3.498

5.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

6.  Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model.

Authors:  Carlos G Leon; Jennifer A Locke; Hans H Adomat; Susan L Etinger; Alexis L Twiddy; Rachel D Neumann; Colleen C Nelson; Emma S Guns; Kishor M Wasan
Journal:  Prostate       Date:  2010-03-01       Impact factor: 4.104

7.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

8.  Androgen receptor gene amplification and protein expression in recurrent prostate cancer.

Authors:  O Harris Ford; Christopher W Gregory; Desok Kim; Andrew B Smitherman; James L Mohler
Journal:  J Urol       Date:  2003-11       Impact factor: 7.450

9.  Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.

Authors:  Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

10.  Effects of sorafenib on C-terminally truncated androgen receptor variants in human prostate cancer cells.

Authors:  Friedemann Zengerling; Wolfgang Streicher; Andres J Schrader; Mark Schrader; Bianca Nitzsche; Marcus V Cronauer; Michael Höpfner
Journal:  Int J Mol Sci       Date:  2012-09-14       Impact factor: 6.208
View more
  17 in total

1.  Symptoms and Impacts in Metastatic Castration-Resistant Prostate Cancer: Qualitative Findings from Patient and Physician Interviews.

Authors:  Stefan Holmstrom; Shevani Naidoo; James Turnbull; Emily Hawryluk; Jean Paty; Robert Morlock
Journal:  Patient       Date:  2019-02       Impact factor: 3.883

2.  [Personalized urooncology based on molecular uropathology: what is the future?].

Authors:  E Dahl; F Haller
Journal:  Urologe A       Date:  2013-07       Impact factor: 0.639

3.  IMPACT Study: Targeted Prostate Cancer Screening.

Authors:  Christos Mikropoulos; Rosalind A Eeles
Journal:  Oncologist       Date:  2013

Review 4.  An update on enzalutamide in the treatment of prostate cancer.

Authors:  Axel S Merseburger; Gabriel P Haas; Christoph-A von Klot
Journal:  Ther Adv Urol       Date:  2015-02

5.  Resistance to "castration-resistant".

Authors:  Lucio Luzzatto
Journal:  Oncologist       Date:  2014-02-17

6.  In reply.

Authors:  Axel S Merseburger; Joaquim Bellmunt; Cheryl Jenkins; Chris Parker; John M Fitzpatrick
Journal:  Oncologist       Date:  2014-02-17

7.  Sonic hedgehog signaling is associated with resistance to zoledronic acid in CD133high/CD44high prostate cancer stem cells.

Authors:  Eda Acikgoz; Gunel Mukhtarova; Araz Alpay; Cigir Biray Avci; Bakiye Goker Bagca; Gulperi Oktem
Journal:  Mol Biol Rep       Date:  2021-05-04       Impact factor: 2.316

8.  MYB interacts with androgen receptor, sustains its ligand-independent activation and promotes castration resistance in prostate cancer.

Authors:  Sanjeev Kumar Srivastava; Mohammad Aslam Khan; Shashi Anand; Haseeb Zubair; Sachin Kumar Deshmukh; Girijesh Kumar Patel; Seema Singh; Joel Andrews; Bin Wang; James Elliot Carter; Ajay Pratap Singh
Journal:  Br J Cancer       Date:  2021-11-26       Impact factor: 9.075

9.  Tumor- and osteoclast-derived NRP2 in prostate cancer bone metastases.

Authors:  Navatha Shree Polavaram; Samikshan Dutta; Ridwan Islam; Arup K Bag; Sohini Roy; David Poitz; Jeffrey Karnes; Lorenz C Hofbauer; Manish Kohli; Brian A Costello; Raffael Jimenez; Surinder K Batra; Benjamin A Teply; Michael H Muders; Kaustubh Datta
Journal:  Bone Res       Date:  2021-05-14       Impact factor: 13.567

10.  Enzalutamide in European and North American men participating in the AFFIRM trial.

Authors:  Axel S Merseburger; Howard I Scher; Joaquim Bellmunt; Kurt Miller; Peter F A Mulders; Arnulf Stenzl; Cora N Sternberg; Karim Fizazi; Mohammad Hirmand; Billy Franks; Gabriel P Haas; Johann de Bono; Ronald de Wit
Journal:  BJU Int       Date:  2014-10-23       Impact factor: 5.588
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.